Explore it now
28th Annual ESGO 2027 Congress
Discover it Now!
ENGOT coordinates and promotes gynaecological cancer clinical trials in Europe
Explore ENGOT
Explore ESGO’s Membership Benefits
Read More
Established in 2019 to fulfil the ESGO vision: Best treatment and prevention in gynaecological cancer, the ESGO Prevention Committee connects more than 70 experts in vaccination, screening, colposcopy, and treatment of pre-invasive disease.
Apart from Prevention webinars, the Prevention Committee produces consensus statements on prevention-related topics. Visit the ESGO Prevention Committee website to learn more about the research we do.
Prof. Elmar Joura chairs the Committee.
October 13, 2026 7-8:30 PM CET
Moderators: Anna Giuliano, Elmar Joura
Webinar abstract:
The webinar examines the clinical controversy surrounding the use of HPV vaccination as an adjuvant (supplemental) treatment for patients who have undergone surgery for cervical precancer (HSIL). The primary learning objective is to understand the "discordance" between observational studies, which suggest a high success rate in preventing recurrence, and Randomized Controlled Trials (RCTs), which show more modest results. Participants will learn to identify common research biases—such as immortal time bias and confounding variables—that may inflate perceived vaccine efficacy. Ultimately, the session aims to clarify that while prophylactic vaccines are designed to prevent new infections rather than treat existing disease, they may still serve as a vital "anchor" for long-term patient recovery and risk reduction. The webinar will be enriched with the patient expert perspective on the topic.
November 19, 2026 3-6 PM CET
Welcome to the third edition of our landmark virtual gathering. This year, we are bridging the gap between cutting-edge clinical research and real-world execution. Healthcare providers, researchers, and public health advocates will walk away with practical, evidence-based strategies to implement directly into their healthcare infrastructure.
By attending this conference, you will learn how to:
Implement simplified logistics: Understand how single-dose protocols and new vaccine options can dramatically scale up your immunization coverage.
Reach the "hard-to-screen": Learn to integrate self-testing and point-of-care (POC) tools to protect rural, high-risk, and HIV-positive populations.
Optimize clinical workflows: Master modern "see-and-treat" algorithms using artificial intelligence (AI) and portable therapeutic devices to prevent loss to follow-up.
The conference is structured into three comprehensive scientific pillars:
1. Vaccination: The latest clinical evidence on single-dose efficacy, insights from the KENSHE Study, new vaccine pipelines (China/India), and scaling blueprints from Botswana and the Rwanda Faster initiative.
2. Screening: Revolutionizing diagnostics via HPV self-testing, Point-of-Care (POC) assays, and risk-based screening in Low-Resource Regions (LRR), alongside optimized protocols for HIV-positive patients.
3. Treatment: Moving from diagnosis to cure using AI-driven colposcopy, portable treatment devices, and structured see-and-treat workflows designed to minimize patient loss to follow-up.
We are proud to host an esteemed international faculty of researchers and clinicians who are actively shaping the elimination landscape across the continent. Meet our featured experts:
Nelly Mugo (Kenya): Presenting critical data from the landmark KENSHE Study regarding single-dose HPV vaccine efficacy.
Francois Uwinkindi (Rwanda): Sharing key national strategy updates from the Rwanda Faster elimination initiative.
Doreen Ramogola-Masire (Botswana): Offering insights into the localized execution and scaling of HPV Vaccination in Botswana.
Anisa Mburu (Kenya): Addressing systemic changes to screening, advocacy, and clinical follow-up protocols for HIV+ women.
Nomonde Mbatani (South Africa): Discussing the practical execution of the See-and-treat algorithm and minimizing patients lost to follow-up.
Hennie Botha (South Africa): Examining the deep-rooted systemic Difficulties for diagnosis and treatment across African healthcare infrastructures.
Ibrahim Friko (Ghana) & Nadja Taumberger (Austria): Co-presenting current clinical breakthroughs and engineering developments in Portable devices in treatment.
Secure your virtual seat today. Join the collective mission to make cervical cancer a disease of the past.
Moderators: Elmar Joura, Murat Gultekin
June 17, 2026 7-8:30 PM CEST
This webinar examines the emerging role of glucagon-like peptide-1 (GLP-1) receptor agonists — originally developed for type 2 diabetes and obesity — in the context of women's cancers and long-term health. Following an overview of available products and their mechanisms, the programme explores associations between GLP-1 receptor agonists and endometrial and breast cancer risk, before concluding with a review of long-term and psychogenic effects, including impacts on mood and appetite regulation. Together, the sessions assess whether GLP-1 receptor agonists represent a genuine clinical breakthrough or a treatment requiring careful, nuanced application.
Advancing HPV Immunization: A Life-Course Approach with a Focus on Adults
May 4, 2026 2-3 PM CEST
World Federation of Public Health Associations (WFPHA) and the European Society of Gynecological Oncology (ESGO) webinar, exploring the role of HPV immunization across the life course, with a particular focus on adult vaccination. While prioritizing adolescent girls remains essential, expanding HPV vaccination to include adults—women and men—is increasingly recognized as a key strategy to reduce the burden of HPV-related diseases, including cancers. This session will bring together leading experts to discuss emerging evidence, clinical perspectives, and policy considerations supporting a more comprehensive and equitable approach to HPV prevention.
April 7, 2026 7-8:30 PM CET
Moderators: Murat Gultekin
Ovarian cancer is now believed to start mainly in the fallopian tubes, not the ovaries.New evidence is changing how doctors understand and prevent this disease.Procedures like salpingectomy are being explored to reduce cancer risk, especially in high-risk women.The webinar also addresses patient choices, ethics, and the role of awareness groups like ENGAGe.
March 25, 2026, 4:30 PM CET
Moderators: Andreia Albuquerque
Participate in this free webinar to gain key insights into Anal Precancerous Lesions in Women: Epidemiology, Screening and Prevention, presented by IPVS and ESGO Prevention. This session will highlight high-risk groups of women, review the new ESGO anal cancer screening guidelines, and explore comprehensive prevention strategies beyond screening, including HPV vaccination, patient education, and lifestyle modification.
December 10, 2025, 4 PM CET
Moderators: Murat Gultekin, Kimon Chatzistamatou
Panelist: Sara Vodopivec
Explore the evolution of colposcopy, a cornerstone in cervical cancer prevention. Learn about its historical development, the key principles behind the procedure, and its vital role in today’s cervical cancer screening programs. Our experts dive into the ongoing advancements in colposcopy, including the integration of cutting-edge technologies like AI, and how these innovations are shaping its future.
November 11, 2025 7-8:30 PM CET
Moderators: Mihaela Grigore, Murat Gultekin
This webinar explored the evolving landscape of oncogenetics with a focus on genetic testing and its role in cancer risk assessment, prevention, and personalized care in gynecologic oncology. Experts discussed the latest advances in genetic screening, including the clinical application of BRCA and Lynch syndrome testing, as well as the emergence of new preventive testing kits now available on the market.
September 10, 2025 7-8:30 PM CET
Moderators: Annette Hasenburg, Murat Gultekin
This webinar will focus on key aspects of psycho-oncology relevant to clinical practice, exploring how healthcare professionals can support and enhance the quality of life of cancer patients throughout the disease trajectory. Discussions will address whether long-term psychological and physical effects of treatment can be anticipated or prevented, and how early supportive interventions may impact survivorship.
July 9, 2025 7-8:30 PM CET
Moderators: Rita Sousa, Murat Gultekin
The session highlights newly available HPV vaccines and their potential impact, as well as the growing body of evidence supporting simplified vaccination schedules, including single-dose strategies. Speakers examine current trends in screening, such as risk-based approaches and the application of high-risk HPV assays that have been validated for primary screening. Special attention will be given to the validation principles required for HPV tests, and to assays that target a limited number of HPV types, exploring their potential role in future screening programs. This webinar offers a comprehensive overview for clinicians, researchers, and public health professionals interested in the evolving landscape of HPV prevention and control.
Moderator: Jalid Sehouli
Moderator: Elmar Joura
Moderator: Murat Gultekin
Moderator: Mario Preti
Moderator: Reda Hemida
This is the second edition of a successful full-day virtual event that attracted 1300+ registered participants in 2024. It is focused on vaccination, screening, colposcopy, and treatment of pre-invasive disease in a limited-resource context.
Check out the programme for more details (available in PDF here):